Theravance Biopharma (TBPH) Assets Average (2014 - 2026)
Theravance Biopharma (TBPH) posted quarterly Assets Average of $478.9 million for Q1 2026, up 37.28% year-over-year from $348.9 million in Q1 2025, and up 6.31% quarter-over-quarter from $450.5 million in Q4 2025.
Theravance Biopharma (TBPH) Assets Average (2014 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported Assets Average for 13 consecutive years, with $478.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 37.28% year-over-year to $478.9 million; the TTM figure through Mar 2026 stood at $478.9 million (up 37.28% YoY), while the FY2025 annual figure was $419.9 million, up 14.07% from the prior year.
- Assets Average improved to $478.9 million in Q1 2026 per TBPH's latest filing, from $450.5 million in the prior quarter.
- Across five years, Assets Average topped out at $685.4 million in Q4 2022 and bottomed at $348.9 million in Q1 2025.
- Historically, Assets Average has averaged $435.6 million across 5 years, with a median of $397.8 million in 2023.
- Annual changes were most pronounced in 2022 — Assets Average jumped 76.22% — and 2023, when it plunged 41.97%.
- Theravance Biopharma's Assets Average stood at $685.4 million in 2022, then sank by 41.97% to $397.8 million in 2023, then slipped by 10.72% to $355.1 million in 2024, then advanced by 26.86% to $450.5 million in 2025, then gained by 6.31% to $478.9 million in 2026.
- Business Quant data shows TBPH's Assets Average at $478.9 million in Q1 2026, $450.5 million in Q4 2025, and $420.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - | 471.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 471.04 Mn |
| Mar 31, 2026 | 478.94 Mn |
| Dec 31, 2025 | 450.52 Mn |
| Sep 30, 2025 | 420.75 Mn |
| Jun 30, 2025 | 384.81 Mn |
| Mar 31, 2025 | 348.87 Mn |
| Dec 31, 2024 | 355.13 Mn |
| Sep 30, 2024 | 359.07 Mn |
| Jun 30, 2024 | 366.67 Mn |
| Mar 31, 2024 | 376.65 Mn |
| Dec 31, 2023 | 397.79 Mn |
| Sep 30, 2023 | 430.11 Mn |
| Jun 30, 2023 | 492.59 Mn |
| Mar 31, 2023 | 572.98 Mn |
| Dec 31, 2022 | 685.45 Mn |
| Sep 30, 2022 | 562.13 Mn |
| Jun 30, 2022 | 358.06 Mn |
| Mar 31, 2022 | 365.09 Mn |
| Dec 31, 2021 | 388.96 Mn |
| Sep 30, 2021 | 416.18 Mn |